Skip to main content
OpenTrials

Clinical trial condition

Demyelinating Diseases

Explore clinical trials studying Demyelinating Diseases. Study availability and eligibility vary by location and protocol.

2,934 public trials 459 recruiting studies
Refine in advanced search Browse all conditions

Demyelinating Diseases trial results

Completed

Natalizumab Re-Initiation of Dosing

NCT00306592

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Phoenix, Arizona, United States
  • Research Site Scottsdale, Arizona, United States
  • Research Site Little Rock, Arkansas, United States
View all 63 locations
View Trial Details
Completed

Safety Study of GBS Following Menactra Meningococcal Vaccination

NCT00575653

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Chronic Disease, +12 more
Locations
  • HealthCore, Inc. Wilmington, Delaware, United States
  • Kaiser Permanente Center for Health Research Hawaii Honolulu, Hawaii, United States
  • Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care Boston, Massachusetts, United States
  • i3 Drug Safety Waltham, Massachusetts, United States
View Trial Details
Completed

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

NCT01462318

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Centennial, Colorado, United States
  • Research Site Washington D.C., District of Columbia, United States
  • Research Site Lake Barrington, Illinois, United States
  • Research Site Lexington, Kentucky, United States
View all 19 locations
View Trial Details
Completed

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

NCT00622700

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +8 more
Locations
  • Investigational Site Number 8965 Cullman, Alabama, United States
  • Investigational Site Number 8954 Phoenix, Arizona, United States
  • Investigational Site Number 8946 Phoenix, Arizona, United States
  • Investigational Site Number 8962 Fort Collins, Colorado, United States
View all 131 locations
View Trial Details
Completed

Rebif® Rebidose® Versus Rebiject II® Ease-of-Use

NCT02019550

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Research site Cullman, Alabama, United States
  • Research Site Tuscon, Arizona, United States
  • Research Site Newport Beach, California, United States
  • Research site Fort Collins, Colorado, United States
View all 21 locations
View Trial Details

Related conditions